Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 2, 2014, Pages 194-202

  Schnoeller, Corinna ^a   Roux, Xavier ^b,c,d,e   Sawant, Devika ^a   Raze, Dominique ^b,c,d,e   Olszewska, Wieslawa ^a   Locht, Camille ^b,c,d,e   Openshaw, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b INSERM U1019   (France)

^c Centre National de la Recherche Scientifique UMR8204   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

^e UNIV LILLE   (France)

Author keywords

Bronchiolitis; Innate immunity; Mucosal immunity; Vaccine; Whooping cough

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; PERTUSSIS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFECT; FEMALE; IMMUNOCOMPETENT CELL; LUNG ALVEOLUS CELL; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS LOAD; WEIGHT REDUCTION;

ADMINISTRATION, INTRANASAL; ANIMALS; BORDETELLA PERTUSSIS; BRONCHIOLITIS, VIRAL; FEMALE; IMMUNITY, INNATE; INTERLEUKIN-17; MICE; MICE, INBRED BALB C; NASAL MUCOSA; PERTUSSIS VACCINE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VACCINES, ATTENUATED;

EID: 84892640386     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201307-1227OC     Document Type: Article

References (50)

1. Smyth RL, Openshaw PJ. Bronchiolitis. Lancet 2006;368:312-322.
2. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen J L L, Bont L, Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013;368:1791-1799.
3. Mascart F, Hainaut M, Peltier A, Verscheure V, Levy J, Locht C. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 2007;25:391-398.
4. Mascart F, Verscheure V, Malfroot A, Hainaut M, Piérard D, Temerman S, Peltier A, Debrie A-S, Levy J, Del Giudice G, et al. Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J Immunol 2003;170:1504-1509.
5. Antoine R, Alonso S, Raze D, Coutte L, Lesjean S, Willery E, Locht C, Jacob-Dubuisson F. New virulence-activated and virulence-repressed genes identified by systematic gene inactivation and generation of transcriptional fusions in Bordetella pertussis. J Bacteriol 2000;182:5902-5905.
6. Mielcarek N, Debrie A-S, Raze D, Bertout J, Rouanet C, Younes AB, Creusy C, Engle J, Goldman WE, Locht C. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2006;2:e65.
7. Li R, Lim A, Phoon MC, Narasaraju T, Ng J K W, Poh WP, Sim MK, Chow VT, Locht C, Alonso S. Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm. J Virol 2010;84:7105-7113.
8. Schnoeller C, Roux X, Sawant D, Raze D, Locht C, Olszewska W, Openshaw PJ. Live attenuated Bordetella pertussis vaccine candidate modulates viral lung inflammation. Presented at the British Society of Immunology Meeting, Liverpool, UK, December 6-12, 2010.
9. Schnoeller C, Roux X, Sawant D, Raze D, Locht C, Olszewska W, Openshaw PJ. Modulation of viral lung inflammation by live attenuated Bordetella pertussis vaccine. Presented at the World Immune Regulation Meeting IV, Davos, Switzerland, March 29-April 1, 2010.
10. Menozzi FD, Gantiez C, Locht C. Identification and purification of transferrin- and lactoferrin-binding proteins of Bordetella pertussis and Bordetella bronchiseptica. Infect Immun 1991;59:3982-3988.
11. Lee D C P, Harker J A E, Tregoning JS, Atabani SF, Johansson C, Schwarze J, Openshaw P J M. CD251 natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol 2010;84:8790-8798.
12. Olszewska W, Ispas G, Schnoeller C, Sawant D, Van de Casteele T, Nauwelaers D, Van Kerckhove B, Roymans D, De Meulder M, Rouan MC, et al. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J 2011;38:401-408.
13. Mielcarek N, Debrie A-S, Mahieux S, Locht C. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin Vaccine Immunol 2010;17:317-324.
14. Harker JA, Godlee A, Wahlsten JL, Lee D C P, Thorne LG, Sawant D, Tregoning JS, Caspi RR, Bukreyev A, Collins PL, et al. Interleukin 18 coexpression during respiratory syncytial virus infection results in enhanced disease mediated by natural killer cells. J Virol 2010;84:4073-4082.
15. Loving CL, Brockmeier SL, Vincent AL, Palmer MV, Sacco RE, Nicholson TL. Influenza virus coinfection with Bordetella bronchiseptica enhances bacterial colonization and host responses exacerbating pulmonary lesions. Microb Pathog 2010;49:237-245.
16. Didierlaurent A, Goulding J, Patel S, Snelgrove R, Low L, Bebien M, Lawrence T, van Rijt LS, Lambrecht BN, Sirard J-C, et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008;205:323-329.
17. Yamaguchi Y, Harker JA, Wang B, Openshaw PJ, Tregoning JS, Culley FJ. Preexposure to CpG protects against the delayed effects of neonatal respiratory syncytial virus infection. J Virol 2012;86:10456-10461.
18. Abu Raya B, Bamberger E, Kassis I, Kugelman A, Srugo I, Miron D. Bordetella pertussis infection attenuates clinical course of acute bronchiolitis. Pediatr Infect Dis J 2013;32:619-621.
19. Dong W, Selgrade MK, Gilmour MI. Systemic administration of Bordetella pertussis enhances pulmonary sensitization to house dust mite in juvenile rats. Toxicol Sci 2003;72:113-121.
20. Ennis DP, Cassidy JP, Mahon BP. Prior Bordetella pertussis infection modulates allergen priming and the severity of airway pathology in a murine model of allergic asthma. Clin Exp Allergy 2004;34:1488-1497.
21. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, Gustafsson PM. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010;65:1045-1052.
22. Kavanagh H, Noone C, Cahill E, English K, Locht C, Mahon BP. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model. Clin Exp Allergy 2010;40:933-941.
23. Li R, Cheng C, Chong SZ, Lim A R F, Goh YF, Locht C, Kemeny DM, Angeli V, Wong W S F, Alonso S. Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models. Allergy 2012;67:1250-1258.
24. Openshaw PJ, Culley FJ, Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 2001;20:S27-S31.
25. Cyr SL, Angers I, Guillot L, Stoica-Popescu I, Lussier M, Qureshi S, Burt DS, Ward BJ. TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model. Vaccine 2009;27:421-430.
26. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva EC, Shah P, Kaplan MJ, Bruce AT. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011;187:490-500.
27. Kumar V, Sharma A. Neutrophils: Cinderella of innate immune system. Int Immunopharmacol 2010;10:1325-1334.
28. McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, Huston G, Tighe M, Hamada H, Sell S, Dutton RW, et al. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 2009;182:7353-7363.
29. Chen L, Watanabe T, Watanabe H, Sendo F. Neutrophil depletion exacerbates experimental Chagas' disease in BALB/c, but protects C57BL/6 mice through modulating the Th1/Th2 dichotomy in different directions. Eur J Immunol 2001;31:265-275.
30. Tateda K, Moore TA, Newstead MW, Tsai WC, Zeng X, Deng JC, Chen G, Reddy R, Yamaguchi K, Standiford TJ. Chemokine-dependent neutrophil recruitment in a murine model of Legionella pneumonia: potential role of neutrophils as immunoregulatory cells. Infect Immun 2001;69:2017-2024.
31. Halfhide CP, Brearey SP, Flanagan BF, Hunt JA, Howarth D, Cummerson J, Edwards S, Hart CA, Smyth RL. Neutrophil TLR4 expression is reduced in the airways of infants with severe bronchiolitis. Thorax 2009;64:798-805.
32. Nembrini C, Marsland BJ, Kopf M. IL-17-producing T cells in lung immunity and inflammation. J Allergy Clin Immunol 2009;123:986-994, quiz 995-996.
33. Loebbermann J, Schnoeller C, Thornton H, Durant L, Sweeney NP, Schuijs M, O'Garra A, Johansson C, Openshaw PJ. IL-10 regulates viral lung immunopathology during acute respiratory syncytial virus infection in mice. PLoS ONE 2012;7:e32371.
34. Sun J, Cardani A, Sharma AK, Laubach VE, Jack RS, Müller W, Braciale TJ. Autocrine regulation of pulmonary inflammation by effector T-cell derived IL-10 during infection with respiratory syncytial virus. PLoS Pathog 2011;7:e1002173.
35. Weiss KA, Christiaansen AF, Fulton RB, Meyerholz DK, Varga SM. Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection. J Immunol 2011;187:3145-3154.
36. McGuirk P, McCann C, Mills K H G. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 2002;195:221-231.
37. Loebbermann J, Thornton H, Durant L, Sparwasser T, Webster KE, Sprent J, Culley FJ, Johansson C, Openshaw PJ. Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunol 2012;5:161-172.
38. Fedele G, Bianco M, Debrie A-S, Locht C, Ausiello CM. Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. J Immunol 2011;186:5388-5396.
39. Andreasen C, Powell DA, Carbonetti NH. Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice. PLoS ONE 2009;4:e7079.
40. Fedele G, Celestino I, Spensieri F, Frasca L, Nasso M, Watanabe M, Remoli ME, Coccia EM, Altieri F, Ausiello CM. Lipooligosaccharide from Bordetella pertussis induces mature human monocyte-derived dendritic cells and drives a Th2 biased response. Microbes Infect 2007;9:855-863.
41. Higgs R, Higgins SC, Ross PJ, Mills K H G. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol 2012;5:485-500.
42. Warfel JM, Merkel TJ. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol 2013;6:787-796.
43. Munir S, Hillyer P, Le Nouën C, Buchholz UJ, Rabin RL, Collins PL, Bukreyev A. Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response. PLoS Pathog 2011;7:e1001336.
44. Priebe GP, Walsh RL, Cederroth TA, Kamei A, Coutinho-Sledge YS, Goldberg JB, Pier GB. IL-17 is a critical component of vaccineinduced protection against lung infection by lipopolysaccharideheterologous strains of Pseudomonas aeruginosa. J Immunol 2008;181:4965-4975.
45. Mukherjee S, Lindell DM, Berlin AA, Morris SB, Shanley TP, Hershenson MB, Lukacs NW. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am J Pathol 2011;179:248-258.
46. Faber TE, Groen H, Welfing M, Jansen K J G, Bont LJ. Specific increase in local IL-17 production during recovery from primary RSV bronchiolitis. J Med Virol 2012;84:1084-1088.
47. Openshaw PJ, Chiu C. Protective and dysregulated T cell immunity in RSV infection. Curr Opin Virol 2013;3:468-474.
48. Habibi MS, Openshaw P J M. Benefit and harm from immunity to respiratory syncytial virus: implications for treatment. Curr Opin Infect Dis 2012;25:687-694.
49. Ho SY, Chua SQ, Foo D G W, Locht C, Chow VT, Poh CL, Alonso S. Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates. Infect Immun 2008;76:111-119.
50. Kammoun H, Roux X, Raze D, Debrie A-S, De Filette M, Ysenbaert T, Mielcarek N, Saelens X, Fiers W, Locht C. Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e. PLoS ONE 2013;8:e59198.